Davis Capital Management
RPRX icon

Davis Capital Management’s Royalty Pharma RPRX Stock Holding History

Davis Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.4K Buy
24
+12
+100% +$708 ﹤0.01% 461
2026
Q2 		$673 Buy
12
+11
+1,100% +$573 ﹤0.01% 559
2026
Q1 		$48 Hold
1
– – ﹤0.01% 582
2025
Q4 		$39 Sell
1
-5
-83% -$191 ﹤0.01% 599
2025
Q3 		$212 Buy
+6
New +$217 ﹤0.01% 567

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Davis Capital Management's RPRX Position: Q3 2026 in Review

Davis Capital Management increased its Royalty Pharma (RPRX) stake by 100% in Q3 2026, buying an estimated $708 and bringing the position to 24 shares worth $1.4K. The position accounts for ﹤0.01% of the portfolio, ranked #461.

Davis Capital Management first reported a position in RPRX in Q3 2025 and has held it in 5 quarters since. 573 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

  • Davis Capital Management held 24 shares of Royalty Pharma worth $1.4K as of Q3 2026.
  • Davis Capital Management bought 12 Royalty Pharma shares in Q3 2026, an estimated $708.
  • Royalty Pharma made up ﹤0.01% of Davis Capital Management's portfolio in Q3 2026, its #461 holding.
  • Davis Capital Management first reported a position in Royalty Pharma in Q3 2025 and has held it in 5 quarters since.
  • 573 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on Davis Capital Management's 13F filing for Q3 2026, filed 8 Oct 2026.